HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The use of a biologic topical haemostatic agent (TachoSil(®)) for the prevention of postoperative bleeding in patients on antithrombotic therapy undergoing thyroid surgery: A randomised controlled pilot trial.

AbstractINTRODUCTION:
Anticoagulants and antiplatelet agents are well-known risk factors for post-operative bleeding. The aim of this prospective, randomized pilot study was to evaluate the effectiveness of a topical haemostatic agent, namely TachoSil, for the prevention of postoperative bleeding in patients on antithrombotic therapy undergoing thyroidectomy. Perioperative management and some distinctive aspects of cervical haematomas were also discussed.
METHODS:
Between January 2012 and May 2014, all patients taking vitamin K antagonists (VKAs) or acetyl salicylic acid (ASA) scheduled for total thyroidectomy were enrolled and randomly allocated to group 1 (standard haemostasis) and group 2 (standard haemostasis + TachoSil). Antithrombotic drugs were always suspended prior to surgery and, when indicated, replaced by bridging anticoagulation with low-molecular-weight heparin. The primary endpoint was the incidence of postoperative cervical haematomas.
RESULTS:
A total of 70 patients were included in the study, representing 8.5% (70/820) of all patients who underwent thyroidectomies in the same period. The overall rate of post-operative cervical haematoma was 7.1% (5/70) and reached 14.8% (4/27) in patients on VKA therapy. All but one occurred more than 24 h after surgery (32nd hour, 8th, 10th, and 13th days). Group 1 (37 patients) and group 2 (33 patients) were well-matched according to clinical and demographic features. Postoperative haematoma was observed in 2/37 patients (5.4%) recruited in the Group 1 and 3/33 patients (9.1%) recruited in the Group 2 (P = 0.661).
CONCLUSIONS:
Patients taking antithrombotic drugs represent a major problem in thyroid surgery. The incidence of bleeding after thyroidectomy is significantly high and the use of TachoSil do not seem effective in preventing its occurrence. However, larger multicenter study is needed to confirm these results.
AuthorsEnrico Erdas, Fabio Medas, Francesco Podda, Silvia Furcas, Giuseppe Pisano, Angelo Nicolosi, Pietro Giorgio Calò
JournalInternational journal of surgery (London, England) (Int J Surg) Vol. 20 Pg. 95-100 (Aug 2015) ISSN: 1743-9159 [Electronic] England
PMID26079499 (Publication Type: Journal Article, Randomized Controlled Trial)
CopyrightCopyright © 2015 IJS Publishing Group Limited. Published by Elsevier Ltd. All rights reserved.
Chemical References
  • Biological Products
  • Drug Combinations
  • Fibrinolytic Agents
  • Hemostatics
  • Heparin, Low-Molecular-Weight
  • TachoSil
  • Vitamin K
  • Fibrinogen
  • Thrombin
  • Aspirin
Topics
  • Administration, Topical
  • Aged
  • Aspirin (therapeutic use)
  • Biological Products (administration & dosage)
  • Drug Combinations
  • Female
  • Fibrinogen (administration & dosage)
  • Fibrinolytic Agents (adverse effects)
  • Hemostatics (administration & dosage)
  • Heparin, Low-Molecular-Weight (therapeutic use)
  • Humans
  • Male
  • Middle Aged
  • Pilot Projects
  • Postoperative Hemorrhage (chemically induced, prevention & control)
  • Prospective Studies
  • Thrombin (administration & dosage)
  • Thyroid Gland (surgery)
  • Thyroidectomy
  • Vitamin K (agonists, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: